Bellevue Group Ag Mirati Therapeutics, Inc. Transaction History

Bellevue Group Ag

$5.93 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$39.16 - $88.71 $579,568 - $1.31 Million	-14,800 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$75.82 - $150.97 $515,575 - $1.03 Million	-6,800 Reduced 31.48%	14,800 $1.22 Million
Q4 2021 Feb 10, 2022	BUY	$132.01 - $190.29 $356,427 - $513,783	2,700 Added 14.29%	21,600 $3.17 Million
Q3 2021 Nov 12, 2021	BUY	$132.13 - $177.45 $1.53 Million - $2.06 Million	11,600 Added 158.9%	18,900 $3.34 Million
Q2 2021 Aug 12, 2021	SELL	$144.0 - $179.73 $360,000 - $449,325	-2,500 Reduced 25.51%	7,300 $1.18 Million
Q1 2021 May 12, 2021	SELL	$158.92 - $221.61 $397,299 - $554,025	-2,500 Reduced 20.33%	9,800 $1.68 Million
Q4 2020 Feb 16, 2021	SELL	$162.05 - $240.27 $891,275 - $1.32 Million	-5,500 Reduced 30.9%	12,300 $2.7 Million
Q2 2020 Aug 13, 2020	BUY	$72.01 - $120.39 $136,819 - $228,741	1,900 Added 11.95%	17,800 $2.03 Million
Q1 2020 May 14, 2020	SELL	$69.78 - $116.21 $27,912 - $46,484	-400 Reduced 2.45%	15,900 $1.22 Million
Q4 2019 Feb 14, 2020	BUY	$70.76 - $128.86 $28,304 - $51,544	400 Added 2.52%	16,300 $2.1 Million
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $436,296 - $613,760	-5,600 Reduced 26.05%	15,900 $1.24 Million
Q2 2019 Aug 14, 2019	BUY	$59.49 - $104.71 $416,430 - $732,970	7,000 Added 48.28%	21,500 $2.22 Million
Q1 2019 May 15, 2019	SELL	$43.65 - $78.95 $414,675 - $750,025	-9,500 Reduced 39.58%	14,500 $1.06 Million
Q4 2018 Feb 12, 2019	SELL	$32.0 - $47.43 $32,000 - $47,430	-1,000 Reduced 4.0%	24,000 $1.02 Million
Q3 2018 Nov 13, 2018	SELL	$47.1 - $62.7 $23,550 - $31,350	-500 Reduced 1.96%	25,000 $1.18 Million
Q2 2018 Aug 07, 2018	BUY	$26.05 - $52.4 $664,275 - $1.34 Million	25,500 New	25,500 $1.26 Million

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account